Microbiome Drug Developer Raises $50m For First-In-Human Studies
Executive Summary
PureTech Health business Vedanta Biosciences Inc. – a company developing a new class of therapies designed to modulate the human microbiome – has raised $50m through new equity investments to advance several of its programs into the clinic.
You may also be interested in...
Microbiome Clinical Studies Loom Large In 2018
Events are moving fast in the microbiome field. The sector is expecting results from numerous initial clinical studies during 2018, from across a spectrum of approaches and mechanisms of action, which could lead to new rounds of financings and M&A activity.
VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs
During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.